Company Profile - Beam Therapeutics Inc


Beam Therapeutics Inc (Beam Therapeutics) is a biotechnology company. The company develops precision genetic medicines to treat serious genetic diseases. It is investigating BEAM-101 targeting sickle cell disease and beta-thalassemia, BEAM-102 against sickle cell disease and BEAM-201 for the treatment of T-cell acute lymphoblastic leukemia. Beam Therapeutics is also evaluating therapies against acute myeloid leukemia, alpha 1 antitrypsin deficiency, glycogen storage disorder 1a and Stargardt disease. It utilizes the REPAIR system for A-to-I (adenosine to inosine) RNA (Ribonucleic acid) editing and RESCUE system for C-to-U (cytidine to uridine) RNA editing. Beam Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 2,665
Revenue (US$ m): 61 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

Beam Therapeutics Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers